Arrowhead Research Corporation (Nasdaq:ARWR) announced today the completion of the merger between Insert Therapeutics, Inc. and Calando Pharmaceuticals, Inc.

Insert Therapeutics, Inc., a majority owned subsidiary of Arrowhead Research Corporation (ARWR), announced today that it has filed with the U.S.

Arrowhead Research Corporation (Nasdaq:ARWR) announced today that interim Phase I data has been published in the 2007 American Society for Clinical Oncology Proceedings (ASCO) (Abstract ID 32638).

PASADENA, Calif., April 16 /PRNewswire-FirstCall/ -- Arrowhead Research Corporation announced today that two of its majority-owned subsidiaries, Insert Therapeutics Inc. and Calando Pharmaceuticals Inc., are presenting data at the 2007 American Association for Cancer Research (AACR) Annual Meeting.

PASADENA, Calif., April 16 /PRNewswire/ -- Insert